Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Lymphoma / Leukemia / Myeloma News

NOXXON Is Awarded Research And Development Grant For First-in-Human Clinical Trial With Spiegelmer(R) NOX-A12

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Blood / Hematology;  Cancer / Oncology;  Clinical Trials / Drug Trials
Article Date: 06 Sep 2009 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

NOXXON Pharma AG (NOXXON), clinical-stage developer of L-RNA based scaffolds (Spiegelmers®) that bind their targets conceptually similar to antibodies, announced that the company was awarded a research grant from Germany's Federal Ministry of Education and Research (BMBF) under the ministry's small and medium enterprise innovation initiative ("KMU-Innovativ"). The grant was presented to NOXXON following the completion of a peer reviewed selection process. Under the initiative NOXXON will receive 1.2 million Euro (1.7 million US$) in funding for the impending phase I clinical development of its candidate Spiegelmer® NOX-A12. The company develops NOX-A12 for use in autologous hematopoietic stem cell transplantation in patients suffering from non-Hodgkin's lymphoma or multiple myeloma.

NOXXON's Chief Executive Officer Frank Morich commented: "In awarding this competitive research grant to NOXXON, the BMBF acknowledges our tremendous progress in maturing Spiegelmer® compounds into therapeutic candidates for human use. The transition from pre-clinical studies to clinical trials is a critical junction in the development of an innovative compound. We are grateful to the BMBF for providing grant support at this crucial stage."

Spiegelmers® (L-aptamers) are chemical entities based on synthetic mirror-image oligonucleotides. Due to their unique mirror image configuration Spiegelmers® are not metabolized and do not hybridize with native nucleic acids. Spiegelmers® also do not activate the innate immune response via Toll-like receptors and have shown an exceptionally favorable immunogenicity profile in pre-clinical testing. The phase I clinical development of NOX-A12 will follow closely behind that of NOXXON's lead candidate NOX-E36, which entered human testing in June of 2009.

Source
NOXXON Pharma AG




Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
What Is Chemotherapy? What Are The Side Effects Of Chemotherapy?
22 Jul 2009
Chemotherapy is the use of chemicals (medication) to treat disease - more specifically, it usually refers to the destruction of cancer cells. However, chemotherapy also includes the use of antibiotics or other medications to treat any disease...


CML Therapy Side Effects image CML Therapy Side Effects

Even "targeted" therapy for chronic myeloid leukemia is not without side effects. Some, like low blood counts, are serious. Hear how one patient, along with her oncologist, Dr. Neil Shah of UCLA, managed the side effects of her CML treatment...

Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

View more videos...